Hospital
City of Wooster
City of Wooster was paid $13.99M by Medicaid between Jan 2018 and Nov 2024, across 222 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoCITY OF WOOSTER
WOOSTER, OH 44691
WOOSTER, OH 44691
33aNPI1437156247assigned 07/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.99M
24GClaims354,413
24DCodes billed222
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#64 of 101
Median peer was paid$22.32M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,710 | $865K | |
| 2019 | 26,612 | $872K | |
| 2020 | 19,492 | $947K | |
| 2021 | 29,076 | $1.14M | |
| 2022 | 34,704 | $1.54M | |
| 2023 | 132,206 | $4.97M | |
| 2024incomplete | 86,613 | $3.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 23,436 | 21,094 | $2.58M |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 8,028 | 6,088 | $2.17M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 17,930 | 16,359 | $2.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 7,974 | 7,025 | $936K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 7,783 | 6,822 | $870K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 6,567 | 1,572 | $425K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 1,656 | 1,308 | $424K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,637 | 1,364 | $397K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.5% | 4,650 | 1,478 | $347K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 879 | 692 | $243K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.7% | 4,034 | 1,432 | $233K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,385 | 1,041 | $195K |
210 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 928 | $180K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,530 | $177K |
| 80053 | Comprehensive metabolic panel | 1.2% | 13,675 | $169K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 1,551 | $148K |
| G0378 | Hospital observation service, per hour | <1% | 1,550 | $136K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,778 | $120K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 339 | $119K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 456 | $114K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,220 | $114K |
| 59025 | Fetal non-stress test | <1% | 724 | $112K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,206 | $88K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 364 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,256 | $78K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,779 | $71K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 711 | $60K |
| 87631 | <1% | 883 | $52K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 494 | $41K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,029 | $40K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,060 | $36K |
| 97162 | <1% | 676 | $35K | |
| 97113 | <1% | 627 | $33K | |
| 97161 | <1% | 490 | $33K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 895 | $33K |
| 80061 | Lipid panel | <1% | 2,672 | $32K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,808 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,015 | $28K |
| 94668 | <1% | 244 | $27K | |
| 86703 | <1% | 832 | $27K | |
| 84439 | <1% | 1,344 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 135 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,541 | $23K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,024 | $22K |
| 76830 | Ultrasound, transvaginal | <1% | 399 | $21K |
| 97164 | <1% | 439 | $21K | |
| 85027 | <1% | 3,751 | $21K | |
| 94060 | <1% | 138 | $20K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,824 | $20K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 65 | $20K |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 198 | $19K |
| 97803 | <1% | 244 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 429 | $18K |
| 86850 | <1% | 804 | $17K | |
| H2020 | Therapeutic behavioral services, per diem | <1% | 96 | $17K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 442 | $17K |
| 87070 | <1% | 1,021 | $16K | |
| 82607 | <1% | 918 | $15K | |
| 86780 | <1% | 782 | $15K | |
| 95886 | <1% | 51 | $14K | |
| 93971 | <1% | 169 | $14K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 826 | $14K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $14K |
| 97166 | <1% | 268 | $13K | |
| H2012 | Behavioral health day treatment, per hour | <1% | 207 | $13K |
| 86900 | <1% | 931 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,334 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,327 | $12K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 280 | $12K |
| 59050 | <1% | 779 | $12K | |
| 82728 | <1% | 757 | $11K | |
| 74018 | <1% | 324 | $11K | |
| 97802 | <1% | 229 | $10K | |
| 84702 | <1% | 607 | $10K | |
| 87077 | <1% | 1,488 | $10K | |
| 87088 | <1% | 1,869 | $10K | |
| 86140 | <1% | 1,035 | $10K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,278 | $10K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 157 | $10K |
| 86803 | <1% | 554 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 56 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,942 | $9K |
| 83735 | <1% | 1,661 | $9K | |
| 87340 | <1% | 446 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 185 | $8K |
| 83516 | <1% | 422 | $8K | |
| 94726 | <1% | 109 | $8K | |
| 94729 | <1% | 109 | $8K | |
| 82570 | <1% | 714 | $7K | |
| 85610 | <1% | 1,695 | $7K | |
| 72100 | <1% | 336 | $7K | |
| 87205 | <1% | 908 | $7K | |
| 80320 | <1% | 1,180 | $7K | |
| 87186 | <1% | 1,466 | $6K | |
| 73610 | <1% | 461 | $6K | |
| 80076 | <1% | 1,633 | $6K | |
| 73630 | <1% | 615 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $6K |
| 83540 | <1% | 670 | $6K | |
| 86235 | <1% | 431 | $6K | |
| 87081 | <1% | 306 | $6K | |
| 82784 | <1% | 578 | $5K | |
| 93017 | <1% | 76 | $5K | |
| 86901 | <1% | 918 | $5K | |
| 96367 | <1% | 124 | $5K | |
| 88304 | <1% | 244 | $5K | |
| 84481 | <1% | 436 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,837 | $5K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,420 | $5K |
| 73030 | <1% | 299 | $5K | |
| 73564 | <1% | 268 | $5K | |
| 85652 | <1% | 1,085 | $5K | |
| 0001A | <1% | 224 | $4K | |
| 86762 | <1% | 230 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 430 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 359 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 29 | $4K |
| 92526 | <1% | 53 | $4K | |
| 12001 | <1% | 36 | $4K | |
| 76642 | <1% | 34 | $4K | |
| 83615 | <1% | 614 | $4K | |
| 81001 | <1% | 10,600 | $4K | |
| 71271 | <1% | 25 | $4K | |
| 83880 | <1% | 603 | $4K | |
| 0002A | <1% | 189 | $4K | |
| 86256 | <1% | 230 | $4K | |
| 83550 | <1% | 536 | $3K | |
| 82950 | <1% | 243 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 112 | $3K |
| 82043 | <1% | 401 | $3K | |
| 73110 | <1% | 178 | $3K | |
| 84484 | <1% | 4,085 | $3K | |
| 90715 | <1% | 138 | $2K | |
| 73130 | <1% | 272 | $2K | |
| 84112 | <1% | 56 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,554 | $2K |
| 76981 | <1% | 47 | $2K | |
| 86225 | <1% | 165 | $2K | |
| 82670 | <1% | 56 | $2K | |
| 84153 | <1% | 104 | $2K | |
| 93970 | <1% | 14 | $2K | |
| 82248 | <1% | 199 | $2K | |
| 83690 | <1% | 2,924 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 259 | $2K |
| 84156 | <1% | 354 | $2K | |
| 36591 | <1% | 163 | $2K | |
| 82140 | <1% | 169 | $2K | |
| 96158 | <1% | 18 | $2K | |
| 82746 | <1% | 230 | $2K | |
| 92523 | <1% | 31 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 28 | $2K |
| 83001 | <1% | 79 | $2K | |
| 73502 | <1% | 87 | $1K | |
| 84146 | <1% | 70 | $1K | |
| 88342 | <1% | 393 | $1K | |
| 99152 | <1% | 18 | $1K | |
| 84100 | <1% | 414 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $1K |
| 82247 | <1% | 69 | $1K | |
| 86480 | <1% | 21 | $1K | |
| 96376 | <1% | 1,215 | $1K | |
| 87075 | <1% | 288 | $1K | |
| 88313 | <1% | 280 | $968.40 | |
| 84550 | <1% | 199 | $936.92 | |
| 82962 | <1% | 1,921 | $932.02 | |
| 82785 | <1% | 87 | $922.00 | |
| 83002 | <1% | 51 | $917.89 | |
| 85730 | <1% | 769 | $915.47 | |
| 84402 | <1% | 28 | $789.15 | |
| 86706 | <1% | 42 | $785.52 | |
| 86038 | <1% | 42 | $776.61 | |
| 86255 | <1% | 69 | $742.31 | |
| 86003 | <1% | 66 | $741.85 | |
| 80074 | <1% | 38 | $731.69 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 17 | $681.92 |
| 70486 | <1% | 17 | $631.99 | |
| 85379 | <1% | 709 | $597.28 | |
| 80164 | <1% | 67 | $589.97 | |
| 84703 | <1% | 2,186 | $586.34 | |
| 80069 | <1% | 26 | $543.66 | |
| 86787 | <1% | 24 | $524.88 | |
| 84165 | <1% | 73 | $488.95 | |
| 81025 | <1% | 1,299 | $484.79 | |
| 81002 | <1% | 240 | $479.68 | |
| 99406 | <1% | 52 | $477.65 | |
| 87040 | <1% | 366 | $459.61 | |
| 83970 | <1% | 29 | $437.29 | |
| 82652 | <1% | 17 | $385.46 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 21 | $320.00 |
| 86376 | <1% | 14 | $293.18 | |
| 73080 | <1% | 42 | $290.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 377 | $261.84 |
| 87807 | <1% | 219 | $224.64 | |
| 86334 | <1% | 27 | $223.90 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 239 | $209.38 |
| 87428 | <1% | 1,152 | $198.08 | |
| 82550 | <1% | 69 | $183.54 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 598 | $182.38 |
| 83605 | <1% | 725 | $180.81 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,960 | $122.21 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 2,438 | $120.01 |
| 72040 | <1% | 14 | $116.78 | |
| 84436 | <1% | 17 | $87.07 | |
| 82565 | <1% | 20 | $79.74 | |
| 84450 | <1% | 20 | $62.02 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $56.71 |
| 73590 | <1% | 32 | $51.83 | |
| 84460 | <1% | 19 | $44.30 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 93 | $44.14 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 543 | $33.08 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 105 | $15.18 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 645 | $9.23 |
| 91300 | <1% | 431 | $2.40 | |
| A9270 | Non-covered item or service | <1% | 1,349 | $1.22 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,622 | $0.85 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 26 | $0.20 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 88 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 54 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 245 | $0.00 |
| 00840 | 0% | 14 | $0.00 | |
| 82077 | 0% | 197 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYES, SCOTT (DIRECTOR OF FISCAL SERVICES CFO)